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A B S T R A C T
The present study examined the effect of dietary niacin supplementation on fat mass, glucose
control, insulin sensitivity, lipid profile, and adiponectin level in diet-induced obese rats.
Male Sprague-Dawley rats (n = 21) were initially divided into 2 groups of seven and four-
teen rats; the group of 14 rats was fed with a high-fat diet (HFD) and the other group of 7
rats consumed the control diet. Eight weeks after the diet regimen started, half of the rats
from the HFD group were shifted to the niacin-supplemented diet (HFND; 1 mg niacin/kg
diet) while the remaining rats continued on the HFD for another 6 weeks. Results obtained
showed that HFD-fed obese rats exhibited significant increase in body weight gain, reduced
glucose tolerance, insulin sensitivity and increased adiposity, as well as altered lipid profile
after 8 weeks of feeding compared with the controls. However, niacin-supplemented rats
showed reduced weight gain and body weight compared with HFD-induced obese rats even
in the absence of a significant difference in the food intake among the groups in the ex-
periment. In addition, the rats showed an improved time-course glucose control and insulin
sensitivity as demonstrated by a significantly lower area under curve (AUC) values for the
glucose curves. The plasma levels of cholesterol, triglycerides and low density lipoprotein
(LDL) returned towards control values in rats supplemented with niacin compared with obese
rats. The findings suggest that niacin exerts beneficial effect on adiposity, glucose toler-
ance and insulin sensitivity, and plasma lipids, and that it specifically modulates the level
of serum adiponectin under obese condition.
© 2015 Mansoura University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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1. Introduction
Obesity is characterized by excessive accumulation or in-
crease in adipose tissue mass [1]. The adipose tissue secretes
numerous bioactive substances [2] collectively known as
adipocytokines. Adiponectin is the most abundant of these
adipocytokines and is known to have anti-inflammatory, anti-
atherogenic and insulin-sensitizing properties [3,4]. It modulates
a number of metabolic processes, including glucose regula-
tion and fatty acid oxidation [5], and plays an important role
in the suppression of metabolic derangements that cause
insulin resistance and type 2 diabetes mellitus (T2DM) [6].
Interestingly, although adiponectin is secreted by adipose
tissue, the plasma level of adiponectin correlates inversely with
adiposity and directly with insulin sensitivity [7–10]. It has been
found that the plasma level of adiponectin in obese individu-
als was lower than in non-obese ones [7]; furthermore, low
adiponectin concentrations in the plasma correlate withT2DM
[11]. However, weight loss and some lipid-modifying drugs, such
as omega-3 fatty acids, statins and niacin, are known to in-
crease adiponectin concentration [4,12].
Niacin (also called nicotinic acid) is an old lipid-modifying
drug that has favourable effects on all traditionally mea-
sured lipid parameters [13,14]. Niacin increases high density
lipoprotein (HDL), but reduces low density lipoprotein (LDL),
cholesterol (CHOL), and triglycerides (TRIG).Animal studies have
shown that niacin stimulates adiponectin secretion in
adipocytes [15,16].A single dose of niacin given orally or through
intra-peritoneal injection acutely increases serum adiponectin
concentrations in rats and mice within minutes, and this effect
is dependent upon activation of the niacin receptor [15]. Others
have also demonstrated that niacin treatment results in in-
creased adiponectinmRNA [16,17].Additionally, niacin enhanced
PPARγ in rabbit adipocytes [18]; PPARγ is a transcription factor
that plays a central role in adipocyte biology, and it regulates
adiponectin gene expression, processing, and secretion [19].
Given that niacin increases adiponectin level, it is conceiv-
able that niacin could improve insulin sensitivity; however,
previous studies reported otherwise [20–23]. For instance,
Grundy et al. [20] suggested niacin may cause some negative
effects on glucose and insulin metabolism by exacerbating
glucose control and insulin sensitivity leading to hyper-
glycaemia. Other studies have also demonstrated that treat-
ment with niacin produced hyperglycaemia and insulin
resistance [24]. Meanwhile, past reports on the adverse effect
of niacin on glucose and insulin sensitivity are limited with
hyperlipidaemic or non-obese subjects.The present study was
therefore carried out to investigate the effect of niacin on adi-
posity, glucose tolerance, insulin sensitivity and adiponectin
level in HFD-induced obese rats.
2. Materials and methods
2.1. Animals, diet and experimental design
The experiment was carried out with male Sprague-Dawley rats
(n = 21) obtained from the Animal House of the College of Medi-
cine, University of Lagos, Lagos, Nigeria.They were divided into
2 groups of seven and fourteen rats, housed in transparent
plastic cages, in environmentally controlled room under stan-
dard temperature (24 ± 2 0C) and humidity (45–64%), with
alternating 12-h light–dark cycles. Generally, the study was con-
ducted in accordance with the internationally accepted
guidelines for laboratory animal use and care [19] and ap-
proved by the Experimentation Ethics Committee on Animal
Use of the College of Medicine of the University of Lagos (2014/
08).The group of 14 rats was fed with a high-fat diet (HFD) and
the group of 7 rats consumed the control diet. Eight weeks after
the diet regimen started, half of the rats from the HFD group
were shifted to the niacin-supplemented diet (NSD; 1mg niacin/
kg diet) while the remaining rats continued on the HFD for
another 6 weeks. Water and food were available ad libitum to
the rats throughout the experimental period, and their diet
intake and body weights were recorded weekly. The compo-
sition of the experimental diets employed in this study is shown
in Table 1.
2.2. Oral glucose tolerance test
Oral glucose tolerance test (OGTT) was performed at the end
of the 14-week experimental period. For this purpose, the
animals were fasted for about 16 h prior to the time the test
commenced. Subsequently, a zero time (baseline) blood sample
was drawn and designated 0 min glucose level.Thereafter, each
rat was given an oral glucose load of 2g/kg BW [20] of glucose
solution (D-Glucose: Sigma Cat. No. G-7528). Blood sample was
drawn from tail vein after the glucose load at intervals of 30,
60, 120 and 180 min for measurement of glucose level. The
glucose level was measured with a portable Acu-Chek glucose
meter (Roche Diagnostics, Germany).
2.3. Insulin tolerance test
Rats that were used for insulin tolerance test (ITT) were fasted
for 4 h. Basal blood glucose levels (0 min) were measured fol-
lowed by injection of insulin (0.5 U/kg BW; Human Insulatard,
Novo Nordisk) into the peritoneum, and blood glucose levels
weremeasured at 15, 30, 60, 120 and 180min by portable glucose
meter using tail vein blood. Total area under the curves (AUC)
in response to glucose or insulin administration was calcu-
lated using GraphPad Prism version 5.00 forWindows, GraphPad
Software, San Diego, California USA.
Table 1 – Composition of experimental diets (unit: g/Kg).
Components Control HFD NSD
Corn flour 529.5 330.5 329.5
Casein 200 200 200
Sucrose 100 100 100
Soybean oil 70 40 40
Cellulose 50 50 50
Mineral mix 35 35 35
Vitamin mix 10 10 10
L-cystine 3 3 3
Choline 2.5 2.5 2.5
Butter 0 229 229
Niacin 0 0 1
Total 1000 1000 1000
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2.4. Visceral fat
Total visceral fat was measured as the sum of epididymal,
omental and retroperitoneal fat deposits, and was used as an
index of obesity in the animals. For this purpose, epididymal,
omental and retroperitoneal fat pads were quickly excised from
the animals at the time of their sacrifice for determining total
visceral fat [25].
2.5. Biochemical analysis
Serum concentrations of TRIG, CHOL, LDL and HDL were de-
termined with an automatic blood chemical analyser (BT 2000
Plus, Germany). Insulin and adiponectin were assayed
using the ELISA Kits (Elabscience, Wuhan, China) according
to the manufacturer’s instruction.All the reagents and samples
were stored at room temperature before conducting the
experiment.
2.6. Statistical analysis
Data are expressed as mean ± standard error of mean (SEM)
and analysed using the ANOVA followed by SNK post-hoc test.
A “p” value below 0.05 was considered to be statistically sig-
nificant. All the analyses were carried out using the GraphPad
Instat Version 3.05 for Window Vista, GraphPad Software, San
Diego, California, USA.
3. Results
3.1. Effects of niacin supplementation on food intake,
body weight and weight gain in obese rats
As indicated in Table 2, there was no significant difference in
the body weight among the groups at the commencement of
the experiment. During the first 8 weeks of the experimental
period, there was a significant (p < 0.01) increase in body
weight of HFD-fed groups 176.29 ± 5.26 g and 166.4 ± 9.61 g
(239.01% and 238.62% increase, respectively) compared with
131.14 ± 5.91 (157.13% increase) of the control group. Supple-
mentation with niacin thereafter however attenuated the gain
in body weight (332.23% gain), which was notably less than
that of HFD only group (425.63% gain) rats at the end of the
experiment. With a value of 212.4 ± 8 g at the end of the 14-
week experimental period, the final body weight of the niacin-
supplemented rats was significantly (p < 0.001) lower when
compared with the HFD-induced obese rats (273.33 ± 4.47 g).
Meanwhile, no significant difference was observed in the
food intake among the groups at weeks 4, 8 and 14 of the
experiment.
3.2. Effects of niacin supplementation on oral glucose
tolerance in obese rats
Niacin supplementation improved the glucose clearance in HFD-
obese rats (Fig. 1). Before the glucose load, the blood glucose
levels at 0 min were significantly different among groups.The
glucose challenge of 2 g/kg dramatically raised the blood glucose
level in all groups at 30 and peaked at 60 min. Only control rats
had their blood glucose level returned to the baseline before
180 min while it remained above the baseline level in both HFD
and niacin-supplemented groups. Fig. 3 shows the area under
curve for the OGTT (AUCGTT); compared with control rats, the
AUCGTT of the obese rats was significantly (p < 0.05) higher;
however, niacin supplementation significantly (p < 0.05) reduced
the AUCGTT in the obese rats.
3.3. Effects of niacin supplementation on insulin
tolerance in obese rats
The effect of niacin supplementation on insulin tolerance
in experimental rats is presented in Fig. 2. After an
intra-peritoneal injection of insulin, there was a significant
decrease in the blood glucose levels of all groups. The blood
glucose level of the control group decreased continuously, and
the lowest level was attained at the 120 min time interval.
However, obese rats and niacin-supplemented rats produced
a lesser degree of fall in their blood glucose level as com-
pared with the control group.This observation was reinforced
with the AUC data for ITT (AUCITT) shown in Fig. 3. The AUCITT
for the obese group of rats was significantly (p < 0.001) higher
than the control rats; however, niacin-supplemented rats
showed a significantly (p < 0.001) lower AUCITT compared with
obese rats.
Table 2 – Body weight, weight gain and food intake in control and experimental rats.
Parameters Timeline Control Obese Obese + niacin
Body weight (g) Baseline 51.00 ± 1.32 52.00 ± 1.23 49.14 ± 1.53
4 weeks 86.14 ± 4.72 115.88 ± 3.88** 111.42 ± 8.51**
8 weeks 131.14 ± 5.91 176.29 ± 5.26** 166.4 ± 9.61**
14 weeks 194.42 ± 4.64 273.33 ± 4.47*** 212.4 ± 8.02###
Food intake (g) Baseline 62.57 ± 3.24 71.14 ± 1.86 72.14 ± 4.50
4 weeks 90.71 ± 3.63 94.29 ± 2.10 96.57 ± 2.99
8 weeks 100.43 ± 2.27 104.71 ± 2.76 107.57 ± 3.79
14 weeks 122.86 ± 2.14 122.86 ± 2.64 128.43 ± 3.73
%Weight gain 4 weeks 68.9 122.84 126.74
8 weeks 157.13 239.01 238.62
14 weeks 281.21 425.63 332.23
Results are presented as mean ± SEM, n = 6. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with control group; ###P < 0.001 compared with obese
group.
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3.4. Effects of niacin supplementation on visceral fat in
obese rats
There was a significant increase in the weight of epididymal
(p < 0.05), omental (p < 0.01) and retroperitoneal (p < 0.05) fat
pads in obese rats compared with the control. The weight of
the omental fat pad was significantly lower (p < 0.01) in the
niacin-supplemented group compared with the obese rats.
However, there was no significant difference in the weight of
the epididymal and retroperitoneal fat pads of niacin-
supplemented rats when compared with their obese
counterparts, although the niacin-supplemented values were
marginally lower (Table 3).
3.5. Effects of niacin supplementation on plasma lipid
profile in obese rats
The level of plasma CHOL in the obese group was signifi-
cantly higher (p < 0.01) than control rats. However, niacin-
supplemented rats showed a significant (p < 0.05) decrease in
CHOL concentration compared with HFD-obese rats. Simi-
larly, obese rats showed a significant (p < 0.05) increase in TRIG
concentration, indicating hypertriglyceridemia as compared
with normal rats. Supplementation with niacin however failed
to attenuate the development of hypertriglyceridemia. HFD-
fed obese rats showed a significant (p < 0.001) increase in LDL
concentration compared with control rats; however, niacin
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Fig. 1 – Glucose response curves during oral-glucose-tolerance test in control and experimental rats. Each point represents
the mean, n = 6.
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Fig. 2 – Glucose response curves during insulin-tolerance test in control and experimental rats. Each point represents the
mean, n = 6.
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supplementation reversed the adverse changes in LDL level.
Plasma HDL concentration was significantly (p < 0.05) reduced
in the HFD-fed obese rats as compared with control rats. Supple-
mentation with niacin produced a significant (p < 0.001) increase
in HDL concentration (Fig. 4).
3.6. Effects of niacin supplementation on serum insulin
and adiponectin levels in obese rats
HFD-fed obese rats showed a significant increase (p < 0.01) in
the insulin concentration accompanied by a significant de-
crease (p < 0.001) in adiponectin concentration compared with
control rats. Supplementation with niacin reversed these re-
sponses in obese rats. The level of serum insulin was
significantly lower (p < 0.05) while adiponectin level was sig-
nificantly higher (p < 0.01) in the niacin-supplemented group
as compared to obese rats (Table 4).
4. Discussion
The results of the present study demonstrate impaired meta-
bolic processes, such as glucose intolerance, insulin insensitivity
and dyslipidemia in HFD-obese rats. Supplementation with
niacin however significantly improved most of the above-
stated metabolic deficits. Even though there was no sign of
toxicity and food intake remained within the range of control
values, supplementation with niacin attenuated weight gain
in obese rats and visceral adiposity as a consequence of lowered
fat accretion [26].
Many studies have demonstrated that obesity influences
glucosemetabolism, insulin sensitivity and inflammation [26],
showing a link between increased adiposity and the develop-
ment of diabetesmellitus. In the present study, supplementation
withniacinmodulates the apparent hyperglycaemia andglucose
intolerance in HFD-obese rats [27–29]. In contrast, some other
studies have also reported a decrease in glucose with niacin
therapy especially in a non-obese condition [30,31].Yang et al.
[29] have reported that niacin treatment has modest improve-
ment on glucose control as it lowers the accumulative AUC
during oral glucose tolerance test in a rodent model of obesity
and type 2 diabetes. However, Li et al. [32] also found that
nicotinamide-treated rats had impaired glucose tolerance and
insulin sensitivity when compared with the control rats. The
inconsistent results observed between studies with obese sub-
jects and non-obese suggest that responses to niacin treatment
may be dependent on specific pathophysiological conditions.
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Fig. 3 – AUC for OGTT and ITT in control and experimental rats. Results are presented as mean ± SEM, n = 6. *P < 0.05
compared with control group; #P < 0.05 compared with obese group.
Table 3 – Weight of epididymal, omental and retroperitoneal fat pads in control and experimental rats.
Parameters Control Obese Obese + niacin
Epididymal fat pad (g) 0.93 ± 0.04 1.15 ± 0.05* 1.01 ± 0.07
Epididymal fat pad/body weight ratio 0.48 0.38 0.48
Omental fat pad (g) 0.85 ± 0.06 1.18 ± 0.05** 0.95 ± 0.05##
Omental fat pad/body weight ratio 0.44 0.4 0.46
Retroperitoneal fat pad (g) 0.98 ± 0.06 1.29 ± 0.09* 1.09 ± 0.09
Retroperitoneal fat pad/body weight ratio 0.5 0.47 0.51
Results are presented as mean ± SEM, n = 6. *P < 0.05 and **P < 0.01 compared with control group; ##P < 0.01 compared with obese group.
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One of the underlying factors for glucose control is insulin,
its level and sensitivity. In this study, niacin supplementa-
tion also enhanced insulin sensitivity in obese rats. Increased
glucose tolerance and reduction in the concentration of plasma
insulin can be related to increased insulin sensitivity and lower
degree of disorder of lipid metabolism [33]. Excess blood lipid
has serious impact on whole body metabolic function and pro-
found negative effect on insulin signalling within the muscle
tissue [34]. Dyslipidemia, which is characterized by elevated
TG, low HDL and increased LDL, usually precedes glucose in-
tolerance and decrease insulin sensitivity through the inhibition
of insulin-mediated glucose transporters in skeletal muscle and
by contributing to hyperinsulinaemia [35]. Controlling
dyslipidemia by niacin in the present study therefore appears
to be an attractive target for improving the aspect of meta-
bolic deficits that result from deleterious hormonal effects of
adipose tissues. An approach to restore insulin sensitivity is
a critical focus to achieving glucose homeostasis under obese
conditions.
Adiponectin is a novel adipocyte-specific protein that has
been suggested to play a role in the development of insulin
resistance and atherosclerosis. Furthermore, reduced expres-
sion of adiponectin has been associated with some degree of
insulin resistance in animal studies, indicating a role for
hypoadiponectinaemia in relation to insulin resistance [36]. In
this study, niacin supplementation significantly increased the
level of serum adiponectin in HFD-induced obese rats.This sug-
gests that the niacin-mediated improvements in glucose control
and insulin sensitivity may in part be due to the alteration of
adiponectin signalling. There is a consensus in literature that
adiponectin generally exerts insulin sensitizing, anti-
inflammatory and anti-apoptotic actions on a number of
different cell types [36]. Because a negative correlation exists
between various hormones (including insulin) associated with
insulin resistance and obesity on one hand, and adiponectin
secretion on the other hand [37], niacin may indirectly mod-
erate insulin secretion via its effect on adiponectin.
In conclusion, the present results suggest that niacin im-
proves adiposity, lipid profile, insulin sensitivity, glucose
tolerance and modulates adiponectin level in obese rats. More
research is needed to determine themodulatory effects of niacin
on adipokines as it greatly influences insulin sensitivity, glucose
metabolism and inflammation, and may provide a molecular
link between increased adiposity and glucose intolerance/
diabetes mellitus.
Acknowledgement
The authors wish to thank Sunday Ogunnowo who provided
technical assistance during the experiments.
R E F E R E N C E S
[1] Vazquez-Vela ME, Torres N, Tovar AR. White adipose tissue
as endocrine organ and its role in obesity. Arch Med Res
2008;39:715–28.
[2] Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin:
more than just another fat cell hormone? Diabetes Care
2003;26:2442–50.
0
0.5
1
1.5
2
2.5
CHOL TRIG HDL LDL
C
on
ce
nt
ra
tio
n 
(m
m
ol
/l)
Control Obese Obese+Niacin
**
#
*
***
##
###
*
Fig. 4 – Plasma concentrations of CHOL, TRIG, HDL and LDL in control and experimental rats. Results are presented as
mean ± SEM, n = 6. *P < 0.05 compared with control group; #P < 0.05 compared with obese group.
Table 4 – Concentration of insulin and adiponectin in
control and experimental rats.
Parameters Control Obese Obese + niacin
Insulin (pmol/l) 693 ± 35 1076 ± 98** 842 ± 64#
Adiponectin (ng/ml) 986 ± 87 651 ± 58*** 813 ± 72##
Results are presented as mean ± SEM, n = 6. *P < 0.05, **P < 0.01 and
***P < 0.001 compared with control group; #P < 0.05 and ##P < 0.01 com-
pared with obese group.
266 e g y p t i an j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 2 ( 2 0 1 5 ) 2 6 1 – 2 6 7
[3] Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and
anti-atherogenic properties of adiponectin. Biochimie
2012;94(10):2137–42.
[4] Han SH, Quon MJ, Kim JA, Koh KK. Adiponectin and
cardiovascular disease: response to therapeutic
interventions. J Am Coll Cardiol 2007;49(5):531–8.
[5] Fagerberg B, Kellis D, Bergstrom G, Behre CJ. Adiponectin in
relation to insulin sensitivity and insulin secretion in the
development of type 2 diabetes: a prospective study in 64-
year-old women. J Intern Med 2011;269:636–43.
[6] Sheng T, Yang K. Adiponectin and its association with
insulin resistance and type 2 diabetes. J Genet Genomics
2008;35:321–6.
[7] Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa
J, et al. Paradoxical decrease of an adipose-specific protein,
adiponectin, in obesity. Biochem Biophys Res Commun
1999;257(1):79–83.
[8] Bambace C, Telesca M, Zoico E, Sepe A, Olioso D, Rossi A,
et al. Adiponectin gene expression and adipocyte diameter:
a comparison between epicardial and subcutaneous adipose
tissue in men. Cardiovasc Pathol 2011;20(5):e153–6.
[9] Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular
effects of adiponectin: molecular mechanisms and
potential therapeutic intervention. Clin Sci (Lond)
2008;114:361–74.
[10] Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K.
Adiponectin and adiponectin receptors in insulin resistance,
diabetes, and the metabolic syndrome. J Clin Invest
2006;116(7):1784–92.
[11] Han SH, Sakuma I, Shin EK, Koh KK. Anti-atherosclerotic and
anti-insulin resistance effects of adiponectin: basic and
clinical studies. Prog Cardiovasc Dis 2009;52:126–40.
[12] Wanders D, Plaisance EP, Judd RL. Pharmacological effects of
lipid-lowering drugs on circulating adipokines. World J
Diabetes 2010;1(4):116–28.
[13] Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and
fibrates in atherogenic dyslipidemia: pharmacotherapy to
reduce cardiovascular risk. Pharmacol Ther 2010;126(3):314–
45.
[14] Song WL, FitzGerald GA. Niacin, an old drug with a new
twist. J Lipid Res 2013;54(10):2586–94.
[15] Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G,
Judd RL. Niacin stimulates adiponectin secretion through
the GPR109A receptor. Am J Physiol Endocrinol Metab
2009;296(3):E549–58.
[16] Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury
RP. Anti-inflammatory effects of nicotinic acid in adipocytes
demonstrated by suppression of fractalkine, RANTES, and
MCP-1 and up-regulation of adiponectin. Atherosclerosis
2010;209(1):89–95.
[17] Linke A, Linke A, Sonnabend M, Fasshauer M, Höllriegel R,
Schuler G, et al. Effects of extended-release niacin
on lipid profile and adipocyte biology in patients with
impaired glucose tolerance. Atherosclerosis 2009;205:
207–13.
[18] Zhao SP, Yang J, Li J, Dong SZ, Wu ZH. Effect of niacin on
LXRalpha and PPARgamma expression and HDL-induced
cholesterol efflux in adipocytes of hypercholesterolemic
rabbits. Int J Cardiol 2008;124(2):172–8.
[19] Astapova O, Leff T. Adiponectin and PPARγ: cooperative and
interdependent actions of two key regulators of metabolism.
Vitam Horm 2012;90:143–62.
[20] Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM,
Fitz-Patrick D, et al. Efficacy, safety, and tolerability of once-
daily niacin for the treatment of dyslipidemia associated
with type 2 diabetes: results of the assessment of diabetes
control and evaluation of the efficacy of niaspan trial. Arch
Intern Med 2002;162(14):1568–76.
[21] Poynten AM, Gan SK, Kriketos AD, O’Sullivan A, Kelly JJ, Ellis
BA, et al. Nicotinic acid-induced insulin resistance is
related to increased circulating fatty acids and fat
oxidation but not muscle lipid content. Metabolism 2003;
52(6):699–704.
[22] Koh Y, Bidstrup H, Nichols DL. Niacin increased glucose,
insulin, and C-peptide levels in sedentary non-diabetic
postmenopausal women. Int J Womens Health 2014;6:913–
20.
[23] Pieper JA. Overview of niacin formulations: differences in
pharmacokinetics, efficacy, and safety. Am J Health Syst
Pharm 2003;60:S9–14, quiz 25.
[24] Chen L, So WY, Li SY, Cheng Q, Boucher BJ, Leung PS.
Niacin-induced hyperglycemia is partially mediated via
niacin receptor GPR109a in pancreatic islets. Mol Cell
Endocrinol 2015;404:56–66.
[25] Kim YW, Kim JY, Lee SK. Surgical removal of visceral fat
decreases plasma free fatty acid and increases insulin
sensitivity on liver and peripheral tissue in monosodium-
glutamate (MSG)-obese rats. J Korean Med Sci 1999;14:539–
45.
[26] Wang W, Basinger A, Neese RA, Christiansen M, Hellerstein
MK. Effects of nicotinic acid on fatty acid kinetics, fuel
selection, and pathways of glucose production in women.
Am J Physiol Endocrinol Metab 2000;279(1):E50–9.
[27] Masoodi M, Kuda O, Rossmeisl M, Flachs P, Kopecky J. Lipid
signaling in adipose tissue: connecting inflammation
and metabolism. Biochim Biophys Acta 2015;1851(4):
503–18.
[28] Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C,
Egan D, et al. Effect of niacin on lipid and lipoprotein levels
and glycemic control in patients with diabetes and
peripheral arterial disease: the ADMIT study: a randomized
trial. Arterial Disease Multiple Intervention Trial. JAMA
2000;284(10):1263–70.
[29] Yang SJ, Choi JM, Kim L, Park SE, Rhee EJ, Lee WY, et al.
Nicotinamide improves glucose metabolism and affects
the hepatic NAD-sirtuin pathway in a rodent model of
obesity and type 2 diabetes. J Nutr Biochem 2014;25(1):66–
72.
[30] Knopp RH, Alagona P, Davidson M, Goldberg AC, Kafonek SD,
Kashyap M, et al. Equivalent efficacy of a time-release form
of niacin (Niaspan) given once-a-night versus plain niacin in
the management of hyperlipidemia. Metabolism
1998;47(9):1097–104.
[31] Chang AM, Smith MJ, Galecki AT, Bloem CJ, Halter JB.
Impaired beta-cell function in human aging: response to
nicotinic acid-induced insulin resistance. J Clin Endocrinol
Metab 2006;91(9):3303–9.
[32] Li D, Tian YJ, Guo J, Sun WP, Lun YZ, Guo M, et al.
Nicotinamide supplementation induces detrimental
metabolic and epigenetic changes in developing rats. Br J
Nutr 2013;110(12):2156–64.
[33] Bluher M. Adipose tissue dysfunction in obesity. Exp Clin
Endocrinol Diabetes 2009;117:241–50.
[34] Bajaj M, Medina-Navarro R, Suraamornkul S, Meyer C,
DeFronzo RA, Mandarino LJ. Paradoxical changes in muscle
gene expression in insulin-resistant subjects after sustained
reduction in plasma free fatty acid concentration. Diabetes
2007;56(3):743–52.
[35] Vitarius JA. The metabolic syndrome and cardiovascular
disease. Mt Sinai J Med 2005;72:257–62.
[36] Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R.
Hormonal regulation of adiponectin gene expression in
3T3- L1 adipocytes. Biochem Biophys Res Commun 2002;290:
1084–9.
[37] Turer AT, Scherer PE. Adiponectin: mechanistic insights and
clinical implications. Diabetologia 2012;55:2319–26.
267e g y p t i an j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 2 ( 2 0 1 5 ) 2 6 1 – 2 6 7
